Tzield Approval Expands to Younger Patients

• by Kathryn Wighton

• April 22, 2026

FDA approves first therapy for warm autoimmune hemolytic anemia

The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.

• by Kathryn Wighton

• August 25, 2026

• 3 min

FDA authorizes continuous ketone monitor

Patients aged 2 years and older with diabetes are eligible to use the wearable.

• by Kathryn Wighton

• August 26, 2026

• 2 min

Rethinking Pediatric Asthma Education Through Large Language Model Generation and Simplification: Randomized Double-Blind Study

• by Tianyi Xu, Yong Yin, Xi Zhang, Wei Wei, Jiajun Yuan, Hansong Wang, Guodong Ding, Wenjie Xue, Ziwei Chen, Sixin Xie, Huiqin Niu, Jie Xi, Shuzhu Lin, Xiaoli Tang, Liebin Zhao

• August 26, 2026